Reuters logo
BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder
October 26, 2017 / 12:07 PM / in 25 days

BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder

Oct 26 (Reuters) - Vistagen Therapeutics Inc

* Vistagen announces fda authorization to initiate phase 2 study of av-101 for major depressive disorder Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below